Dermatology, Immune Response and Research - Clinical Research Informer

World Psoriasis Day 2024: New Treatments and Research Trends

XTalks

OCTOBER 24, 2024

Trends in Psoriasis Research: Biologics, Biosimilars and New Therapies Recent innovations in biologics and biosimilars have transformed psoriasis care. Trends in Psoriasis Research: Biologics, Biosimilars and New Therapies Recent innovations in biologics and biosimilars have transformed psoriasis care.

Research

Research Dermatology Clinical Trials Clinical Trials

Leqselvi Can Achieve Nearly 90% Scalp Hair Coverage in Severe Alopecia Areata Patients

XTalks

JULY 31, 2024

Alopecia areata can be triggered by genetics, immune system dysfunction and environmental factors. Leqselvi works by selectively inhibiting the Janus kinases (JAK) JAK1 and JAK2, pathways that play a key role in this misguided immune response.

Immune Response

Immune Response Dermatology Clinical Trials Clinical Trials

Study reveals details of immune defense guidance system

Scienmag

MARCH 3, 2021

Results could lead to better drugs used to fight inflammation At the beginning of an immune response, a molecule known to mobilize immune cells into the bloodstream, where they home in on infection sites, rapidly shifts position, a new study shows.

Immune Response

Immune Response Drugs Research Dermatology

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

What is Hidradenitis Suppurativa: Signs, Causes and Treatments

Olympian Clinical Research

NOVEMBER 16, 2022

According to the American Academy of Dermatology , scientists believe that when a hair follicle becomes clogged with keratin, bacteria breed within it. HS is believed to develop due to an immune response that generates too much inflammation. More research is still needed to understand the causes of HS fully.

Clinical Research

Clinical Research Bacteria Dermatology Immune Response

Next Generation Complement Therapeutics: Potential Life-Changing Therapies for Multiple Rare Disorders

Roots Analysis

MARCH 3, 2022

The complement-targeted therapeutics inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens. Published Scientific Literature: Indicative of the Ongoing pace of Research in this Field. Next Generation Complement Therapeutics.

Drug Delivery Systems

Drug Delivery Systems Marketing Immune Response Dermatology

Novel drug combo activates natural killer cell immunity to destroy cancer cells

The Pharma Data

JUNE 19, 2022

This occurs occurs over time as cancer patients are treated with drugs to enhance T-cell mediated immunity,” said Gavin Robertson, professor of pharmacology, pathology, dermatology and surgery, Penn State College of Medicine. In addition, the researchers found that the drug combination was not toxic to the animals.

Drugs

Drugs Protein Immune Response Scientist

Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis

The Pharma Data

OCTOBER 9, 2021

Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by an irregular, chronic immune response that creates inflammation and ulcers (sores) in the mucosa (lining) of the large intestine (colon) or rectum. Deucravacitinib is not approved for use in any country. About Ulcerative Colitis.

Trials

Trials Immune Response Dermatology Clinical Trials

New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

The Pharma Data

APRIL 28, 2021

These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14.

Dermatology

Dermatology Trials Clinical Trials Clinical Trials

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

The Pharma Data

SEPTEMBER 15, 2020

I am proud of the truly transformational science that our research and clinical teams are bringing to the fight against disease, as well as the unprecedented speed with which we are advancing our clinical programs in the battle against COVID-19. THERAPEUTIC AREAS OF FOCUS. Inflammation and Immunology.

Gene Therapy

Gene Therapy Vaccination Vaccine Trials

New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable

The Pharma Data

MARCH 16, 2021

These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021. Vice President, Rheumatology Disease Area Leader, Janssen Research & Development, LLC. 1,2 TREMFYA is the first and only IL-23 inhibitor therapy approved in the U.S.

Medicine

Medicine Doctors Doctor Development

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication

The Pharma Data

JULY 23, 2021

The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response.

Hormones

Hormones Trials Genome Genomics

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Hepatocellular Carcinoma U.S. Indication

The Pharma Data

MARCH 11, 2021

The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response.

Trials

Trials Hormones Genome Genomics

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

The Pharma Data

APRIL 4, 2023

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue and can affect more than one body system simultaneously. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

FDA Approval

FDA Approval Containment Hormones Dermatology

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

The Pharma Data

AUGUST 11, 2020

Bristol Myers Squibb: Advancing Cancer Research. The goal of our cancer research is to increase patients’ quality of life, long-term survival and make cure a possibility. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers. About Opdivo.

Trials

Trials Hormones Clinical Trials Clinical Trials

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

The Pharma Data

AUGUST 11, 2020

Bristol Myers Squibb: Advancing Cancer Research. The goal of our cancer research is to increase patients’ quality of life, long-term survival and make cure a possibility. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers. About Opdivo.

Trials

Trials Hormones Clinical Trials Clinical Trials

Top 10 Best-Selling Immunology Drugs by Recent Sales Data

XTalks

JANUARY 2, 2025

Skyrizis targeted mechanism of action and long-lasting effectiveness have positioned it as a leading choice among modern biologics in dermatology. In addition, AbbVie continues to invest in research and development.

Sales

Sales FDA Approval Drugs Marketing

Clinical Research Informer

World Psoriasis Day 2024: New Treatments and Research Trends

Leqselvi Can Achieve Nearly 90% Scalp Hair Coverage in Severe Alopecia Areata Patients

Webinars

Trending Sources

Study reveals details of immune defense guidance system

Webinars

What is Hidradenitis Suppurativa: Signs, Causes and Treatments

Next Generation Complement Therapeutics: Potential Life-Changing Therapies for Multiple Rare Disorders

Novel drug combo activates natural killer cell immunity to destroy cancer cells

Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis

New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Hepatocellular Carcinoma U.S. Indication

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

Top 10 Best-Selling Immunology Drugs by Recent Sales Data

Stay Connected